On June 18, LG Chem announced a collaboration with UK-based LabGenius Therapeutics, signing a joint research and development and option exercise agreement for multiple antibody-based anti-cancer drug candidates. LG Chem will pay an upfront fee and R&D expenses, and both parties will decide whether to exercise subsequent development and licensing rights based on the joint research results.
